{"id":"NCT02815280","sponsor":"Vyne Therapeutics Inc.","briefTitle":"A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne","officialTitle":"A Randomized, Double-Blind Study to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of FMX-101 for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris, Study FX2014-05","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05","primaryCompletion":"2017-10-13","completion":"2017-10-13","firstPosted":"2016-06-28","resultsPosted":"2020-11-24","lastUpdate":"2022-01-18"},"enrollment":495,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"FMX-101, 4% minocycline foam","otherNames":[]},{"type":"DRUG","name":"Vehicle Foam","otherNames":[]}],"arms":[{"label":"FMX-101, 4% minocycline foam","type":"EXPERIMENTAL"},{"label":"Vehicle Foam","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase 3 study to evaluate the efficacy, safety and long-term safety of the topical administration of FMX-101, 4% minocycline foam for the treatment of moderate-to-severe acne vulgaris.","primaryOutcome":{"measure":"Absolute Change From Baseline in the Inflammatory Lesion Count at Week 12","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"FMX-101, 4% Minocycline Foam","deltaMin":13.78,"sd":0.66},{"arm":"Vehicle Foam","deltaMin":10.64,"sd":0.94}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0051"}]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":36,"countries":["United States","Dominican Republic"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":333},"commonTop":["Nasopharyngitis","Headache"]}}